Forget Vertex Pharmaceuticals -- CRISPR Therapeutics is a better buy right now.
Purdue Biologist Stanton B. Gelvin explained how Agrobacterium moves DNA into wounded plant cells, and why cracking that “black box” matters for agriculture during a seminar Wednesday afternoon at the ...
February 25, 2026 marks one year since KJ, an infant born with severe carbamoyl phosphate synthetase 1 (CPS1) deficiency, became the world's first person to receive a personalized CRISPR-based gene ...
After teasing a new regulatory process for personalized genetic medicines at the end of last year, the FDA today unveiled draft guidance for an approval pathway that could see custom CRISPR therapies, ...
One of the reasons why rare disease, medications take so long to get to the clinic is because we have very specific ...
"Gene editing takes centre stage in FDA’s new rare disease approval pathway" was originally created and published by ...
Mars is leaning harder into M&M’s as a strategic growth engine while navigating major acquisitions, volatile cocoa markets, ...
Axios on MSN
FDA smooths reviews of rare disease treatments
The Food and Drug Administration on Monday laid out a new pathway aimed at spurring novel individualized treatments targeting ...
ADRIAN WOOLFSON, scientist and founder of Genyro, has authored a brave new book, 'On the Future of Species'. Here, Woolfson examines with SUCHETA DASGUPTA the future of humanity in a world of AI ...
Can Ben Lamm save the planet? He thinks so. Short, stocky and unassuming with a puckish sense of humor, the shaggy-haired ...
Regenerative Medicine Market OverviewThe regenerative medicine market is projected to grow at a robust CAGR of 17% during the forecast period, driven by rising chronic disease incidence, increasing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results